epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2024-23-1-77-88epidemiology-1942Research ArticleОБЗОРREVIEWИммуногенность и безопасность 13-валентной конъюгированной пневмококковой вакцины у больных ревматоидным артритомImmunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritishttps://orcid.org/0000-0001-8804-2122БатожаргаловаБ. Ц.BatozhargalovaB. T.

Баирма Цыдендамбаевна Батожаргалова – д. м. н., ведущий научный сотрудник лаборатории вакцинопрофилактики и иммунотерапии аллергических заболеваний,

Москва,

тел. +7 (915)319-07-22. 

Bairma T. Batozhargalova – Dr. Sci. (Med.), Leading Researcher, Laboratory of Vaccination and Immunotherapy of Allergic Diseases,

Moscow,

phone+7 (915)319-07-22.

bairma74@mail.ruhttps://orcid.org/0000-0002-1382-9403КостиновМ. П.KostinovM. P.

Михаил Петрович Костинов – чл.-корр. РАН, д. м. н., профессор, заведующий лабораторией вакцинопрофилактики и иммунотерапии аллергических заболеваний; заведующий кафедрой эпидемиологии и современных технологий вакцинации,

Москва,

тел. +7 (963) 782-35-23.

Mikhail P. Kostinov – corresponding member RAS, Dr. Sci. (Med.), Professor, Head of the Laboratory of Vaccination and Immunotherapy of Allergic Diseases; Head of the Department of Epidemiology and Modern Technologies of Vaccination,

Moscow,

phone +7 (963) 782-35-23.

https://orcid.org/0000-0002-7280-6877ШмитькоА. Д.ShmitkoA. D.

Анна Дмитриевна Шмитько – к. м. н., старший научный сотрудник лаборатории вакцинопрофилактики и  иммунотерапии аллергических заболеваний,

Москва,

тел. +7 (926) 374-45-25.

Anna D. Shmitko – Cand. Sci. (Med.), Senior Research Fellow, Laboratory of Vaccination and Immunotherapy of Allergic Diseases,

Moscow,

phone +7 (926) 374-45-25.

violadellanna@gmail.comhttps://orcid.org/0000-0001-7958-5926ЛукинаГ. В.LukinaG. V.

Галина Викторовна Лукина – д. м. н, профессор, заведующий отделом ревматологии; ведущий научный сотрудник лаборатории эволюции ревматоидного артрита,

Москва,

тел. +7 (916) 675-96-02.

Galina V. Lukina – Dr. Sci. (Med.), Professor, Head of the Department of Rheumatology; Leading Clinical Researcher, Laboratory of the Evolution of Rheumatoid Arthritis,

Moscow,

phone +7 (916) 675-96-02.

gvl3@yandex.ruhttps://orcid.org/0000-0002-8143-0058МуртазалиеваД. А.MurtazalievaD. A.

Джамиля Абдуловна Муртазалиева  – врач-ревматолог,

Москва,

тел. +7 (985) 806-69-30.

Jamilya A. Murtazalieva – Rheumatologist,

Moscow,

phone+7 (985) 806-69-30.

artur_m-a18@mail.ruhttps://orcid.org/0000-0002-5202-4878КольцоваЕ. Н.KoltsovaE. N.

Екатерина Николаевна Кольцова – к. м. н., врач-ревматолог,

Москва,

тел. +7 (919) 107-44-26.

Ekaterina N. Koltsova – Cand. Sci. (Med.), Rheumatologist,

Moscow,

phone +7 (919) 107-44-26.

e.n.koltsova@yandex.ruhttps://orcid.org/0000-0002-9443-1164ЖиляевЕ. В.ZhilyaevE. V.

Евгений Валерьевич Жиляев – д. м. н, профессор, заместитель главного врача по лечебной работе; профессор кафедры ревматологии; профессор кафедры факультетской терапии им. академика А. И. Нестерова,

Москва.

Evgenii V. Zhilyaev – Dr. Sci. (Med.), Professor,

Moscow.

zhilyayevev@mail.ruФГБНУ «НИИ вакцин и сывороток им. И.И. Мечникова»РоссияFederal State Budgetary Scientific Institution «I.Mechnikov Research Institute of Vaccines and Sera»Russian FederationФГБНУ «НИИ вакцин и сывороток им. И.И. Мечникова»; ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский университет) Минздрава РоссииРоссияFederal State Budgetary Scientific Institution «I.Mechnikov Research Institute of Vaccines and Sera»; I.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationГБУЗ Московский клинический научный центр им. А. С. Логинова ДЗМ; ФГБНУ НИИ ревматологии им. В.А. НасоновойРоссияA.S. Loginov Moscow Clinical Scientific Center; V.A. Nasonova Research Institute of RheumatologyRussian FederationГБУЗ Московский клинический научный центр им. А. С. Логинова ДЗМРоссияA.S. Loginov Moscow Clinical Scientific CenterRussian FederationАО «Европейский Медицинский Центр»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РоссииРоссияCJSC «European Medical Center»; Russian Medical Academy of Continuing Professional Education Ministry of Health of Russia; Russian National Research Medical University named after N.I. Pirogov" Ministry of Health of RussiaRussian Federation2024030320242317788Copyright © Батожаргалова Б.Ц., Костинов М.П., Шмитько А.Д., Лукина Г.В., Муртазалиева Д.А., Кольцова Е.Н., Жиляев Е.В., 20242024Батожаргалова Б.Ц., Костинов М.П., Шмитько А.Д., Лукина Г.В., Муртазалиева Д.А., Кольцова Е.Н., Жиляев Е.В.Batozhargalova B.T., Kostinov M.P., Shmitko A.D., Lukina G.V., Murtazalieva D.A., Koltsova E.N., Zhilyaev E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1942

Актуальность. Пневмококки относятся к наиболее распространенным возбудителям тяжелых бактериальных инфекций человека. Распространенность инвазивных пневмококковых инфекций среди лиц с аутоиммунными воспалительными ревматическими заболеваниями в 3–4 раза выше, чем в общей популяции. Цель. Оценить эффективность вакцинации 13-валентной конъюгированной пневмококковой вакциной (ПКВ 13) пациентов с ревматоидным артритом (РА) на фоне приема различных препаратов. Материалы и методы. В обзоре использовались данные научных публикаций PubMed, Web of Science, elibrary, Национальной базы данных стационаров США, Московского единого регистра артритов, НИИ ревматологии им. В. А. Насоновой. Заключение. Результаты обзора свидетельствуют: больные РА, получающие препараты тсБПВП, ГИБП и ГК (<15 мг в сутки), после вакцинации ПКВ 13 способны вырабатывать антитела на защитном уровне к определенным серотипам пневмококка, при этом вакцинация не сопровождается серьезными нежелательными явлениями и не влияет на активность ревматоидного артрита. Лечение метотрексатом у больных РА уменьшало иммунный ответ и функциональную активность антител. На формирование иммунитета оказывает влияние пожилой возраст пациентов.>< 15мг в сутки), после вакцинации ПКВ 13 способны вырабатывать антитела на защитном уровне к определенным серотипам пневмококка, при этом вакцинация не сопровождается серьезными нежелательными явлениями и не влияет на активность ревматоидного артрита. Лечение метотрексатом у больных РА уменьшало иммунный ответ и функциональную активность антител. На формирование иммунитета оказывает влияние пожилой возраст пациентов.

Relevance. Pneumococci are among the most common causative agents of severe bacterial infections in humans. The prevalence of invasive pneumococcal infections among people with autoimmune inflammatory rheumatic diseases is 3–4 times higher than in the general population. Aim. To evaluate the effectiveness of vaccination with 13-valent pneumococcal conjugate vaccine (PCV 13) in patients with rheumatoid arthritis (RA). Materials and Methods. The data of scientific publications PubMed, Web of Science, elibrary, the National Inpatient Database of the USA, the Moscow Unified Register of Arthritis, the V. A. Nasonova Research Institute of Rheumatology were used in the review. V. A. Nasonova Research Institute of Rheumatology. Conclusion. In the presented review in adult patients with rheumatoid arthritis (RA) receiving various antirheumatic drugs, the immunogenicity (humoral response, opsonophagocytic activity), safety of vaccines of 13-valent conjugated pneumococcal vaccine (PCV13) was assessed. Based on the data presented, a conclusion was made about the safe management of PCV13 and the formation of antibodies to pneumococcus in RA patients with targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), biologic (bDMARDs) and Glucocorticoids (GCs < 15 mg daily). Methotrexate (MTX) in RA patients reduced the pneumococcal response and the functional activity of antibodies.

ПКВ 13вакцинацияревматоидный артритиммуногенностьбезопасностьPCV13vaccinationrheumatoid arthritisimmunogenicitysafetyReferencesCenters for Disease Control and Prevention. ABCs Report: Streptococcus pneumoniae, 2018. Доступно на: https://www.cdc.gov/abcs/reports-findings/survreports/spneu18.html (2018).Centers for Disease Control and Prevention. ABCs Report: Streptococcus pneumoniae, 2018. Avaible at: https://www.cdc.gov/abcs/reports-findings/survreports/spneu18.html (2018).Nobuhiro AN, Hiroshige MH. Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults. Microorganisms. 2021 Nov 12;9(11):2342.Nobuhiro AN, Hiroshige MH. Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults// Microorganisms. 2021 Nov 12;9(11):2342.Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin. Microbiol. Infect. 2014;20(Suppl 5):45–51.Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease //Clin. Microbiol. Infect. 2014;20(Suppl 5):45–51.Aalst M, Lotsch F, Spijker R, et al. Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis. Travel Med Infect Dis. 2018.24:89–100.Aalst M, Lotsch F, Spijker R, et al. Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis. Travel Med Infect Dis. 2018.24:89–100.Chalmers JD, Campling J, Dicker A, et al. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med. 2016;16:77.Chalmers JD, Campling J, Dicker A, et al. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med. 2016;16:77.Backhaus E., Berg S., Andersson R., et al. Epidemiology of invasive pneumococcal infections: Manifestations, incidence and case fatality rate correlated to age, gender and risk factors // BMC Infect. Dis. 2016;16:367.Backhaus E., Berg S., Andersson R., et al. Epidemiology of invasive pneumococcal infections: Manifestations, incidence and case fatality rate correlated to age, gender and risk factors // BMC Infect. Dis. 2016;16:367.Chen H, Matsumoto H, Horita N, et al. Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis. Sci Rep. 2021 Jun 4;11(1):11865.Chen H, Matsumoto H, Horita N, et al. Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis. Sci Rep. 2021 Jun 4;11(1):11865.Shigayeva A, Rudnick W, Green K, et al. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016;62(2):139–47.Shigayeva A, Rudnick W, Green K, et al. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016;62(2):139–47.Potera J, Kambhatla S, Gauto-Mariotti E, Manadan A. Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis. Clin Rheumatol. 2021. 40(12):4845–4851.Potera J, Kambhatla S, Gauto-Mariotti E, Manadan A. Incidence, mortality, and national costs of hospital admissions for potentially preventable infections in patients with rheumatoid arthritis. Clin Rheumatol. 2021. 40(12):4845–4851.Holland-Fischer M, Thomsen RW, Tarp U, Nørgaard M. Prognosis of pneumonia in patients with rheumatoid arthritis: the role of medication and disease activity prior to admission a population-based cohort study. RMD Open 2020;6:e001102.Holland-Fischer M, Thomsen RW, Tarp U, Nørgaard M. Prognosis of pneumonia in patients with rheumatoid arthritis: the role of medication and disease activity prior to admission a population-based cohort study. RMD Open 2020;6:e001102.Жиляев Е. В., Лукина Г. В., Мартазалиева Д. А. и др. Влияние пневмококковой вакцинации на риск развития инфекционных осложнений у пациентов с ревматоидным артритом, получающих лечение таргетными противовоспалительными препаратами (данные Московского Единого Регистра Артритов (МЕРА)). РМЖ. 2021. (7):7–12.Zhilyaev EV, Lukina GV, Murtazalieva DA, et al. The effect of pneumococcal vaccination on the risk of infectious complications in patients with rheumatoid arthritis treated with targeted anti-inflammatory drugs (data from the Moscow Unified Arthritis Registry (MUAR)). RMJ. 2021;7:7–12 (In Russ.).Белов Б. С., Полянская М. В., Балабанова Р. М. Пневмонии при ревматических заболеваниях. Научно-практическая ревматология. 2009;47(3):67–73.Belov B.S., Polyanskaya M.V., Balabanova R.M. Pneumonia in rheumatic diseases. Rheumatology Science and Practice. 2009;47(3):67–73 (In Russ.). doi: 10.14412/1995-4484-2009-1315Чучалин А. Г., Брико Н. И., Авдеев С. Н. и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019. 29(1): 19–34.Chuchalin AG, Briko, NI, Avdeev SN, et al. Federal clinical guidelines on preventive vaccination against pneumococcal infections in adults. Pulmonologiya. 2019;29(1):19–34 (In Russ.). DOI: 10.18093/0869-0189-2019-29-1-19-34.Руководство по клинической иммунологии в респираторной медицине. Костинов М. П., Чучалина А. Г., ред. Издание 2-е, дополненное. М.: Группа МДВ, 2018.– 304с.Guidelines for Clinical Immunology in Respiratory Medicine. Ed.: Kostinova MP, Chuchalina A G. 2nd edition, supplemented. M.: MDF Group, 2018.–304 p. (In Russ.).Драпкина О. М., Брико Н. И., Костинов М. П. и др. Иммунизация взрослых. Методические рекомендации. ФГБУ «НМИЦ ТПМ» Минздрава России:2020. – 248 с.Immunization of adults. Methodological recommendations. Drapkina OM, Briko NI, Kostinov MP, and others of the Federal State Budgetary Institution «NMHC TPM» of the Ministry of Health of Russia:2020. – 248 p. ISBN: 978-5-6043991-3-2. Avaible at: https://www.elibrary.ru/item.asp?id=43138571. (In Russ.).Пособие для врачей-терапевтов. Краткие алгоритмы ведения пациентов на этапе оказания первичной медико-санитарной помощи. Драпкина О. М., Алексеенко С. А., Багдасарян А. А. и др., Москва, 2019. 34 с.A manual for internists. Brief algorithms for managing patients at the stage of primary health care. Ed. Drapkina OM, Alekseenko S A, Bagdasaryan A, et al. – Moscow, 2019:34. Avaible at: www.fesmu.ru/SITE/files/editor/file/News/News/2602191.pdf. (In Russ.).van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic disease.Ann Rheum Dis. 2011 Mar;70(3):414–22.van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic disease.Ann Rheum Dis. 2011 Mar;70(3):414–22.Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020.79(1):39–52.Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020.79(1):39–52.Nguyen M, Lindegaard H, Hendricks O, Friis-Møller N. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol. 2017.46(6):446–453.Nguyen M, Lindegaard H, Hendricks O, Friis-Møller N. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA)// Scand J Rheumatol. 2017.46(6):446–453.Hmamouchi I, Winthrop K, Launay O, Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort.Vaccine. 2015. 17;33(12):1446–52.Hmamouchi I, Winthrop K, Launay O, Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort.Vaccine. 2015. 17;33(12):1446–52.Salemi S, D’Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol. 2010.29(3):270–314.Salemi S, D’Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol. 2010.29(3):270–314.Буханова Д. В., Сергеева М. С., Белов Б. С. и др. Иммуногенность и эффективность 23-валентной п невмококковой вакцины у больных ревматоидным артритом: результаты 5-летнего наблюдения. Современная ревматология. 2018.12(4):85–88.Bukhanova DV, Sergeeva MS, Belov BS, et al. Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study. Modern Rheumatology Journal. 2018;12(4):85–88 (In Russ.). doi: 10.14412/1996-7012-2018-4-85-88.Rákóczi É , Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017 Sep 14;3(2):e000484.Rákóczi É, Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017 Sep 14;3(2):e000484. doi: 10.1136/rmdopen-2017-000484.Kapetanovic MC, Nagel J, Nordström I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017. 7;35(6):903–908.Kapetanovic MC, Nagel J, Nordström I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017;Feb 7;35(6):903–908. doi: 10.1016/j.vaccine.2016.12.068.Nived P, Saxne T, Geborek P, et al. Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment.BMC Rheumatol. 2018.5;2:12.Nived P, Saxne T, Geborek P, et al. Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment. BMC Rheumatol. 2018;Apr 5;2:12. doi: 10.1186/s41927-018-0019-6.Nived P, Pettersson Å, Jönsson G, et al. Methotrexate reduces circulating Th17 cells and impairs plasmablast and memory B cell expansions following pneumococcal conjugate immunization in RA patients. Sci Rep. 2021. 28;11(1):9199.Nived P, Pettersson Å, Jönsson G, et al. Methotrexate reduces circulating Th17 cells and impairs plasmablast and memory B cell expansions following pneumococcal conjugate immunization in RA patients. Sci Rep. 2021;Apr 28;11(1):9199. doi: 10.1038/s41598-021-88491-2.Elmér E, Per Nived P, Pettersson A, et al. Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients. J Immunol Res.2022. 28;2022:7561661.Elmér E, Per Nived P, Pettersson A, et al. Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients. J Immunol Res. 2022;Jul 28;2022:7561661. doi: 10.1155/2022/7561661.Winthrop KL, Bingham CO, Komocsar WJ, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019. 18;21(1):102.Winthrop KL, Bingham CO, Komocsar WJ, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019;Apr 18;21(1):102. doi: 10.1186/s13075-019-1883-1.Winthrop K, Vargas JI, Drescher E, et al. Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study. RMD Open. 2022. 8(1):e002110.Winthrop K, Vargas JI, Drescher E, et al. Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study. RMD Open. 2022;Mar;8(1):e002110. doi: 10.1136/rmdopen-2021-002110.Mori S, Ueki Y, Ishiwada N. Impact of Janus Kinase Inhibitors on Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine in Patients with Rheumatoid Arthritis. Mod Rheumatol. 2022. 26;roac029.Mori S, Ueki Y, Ishiwada N. Impact of Janus Kinase Inhibitors on Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine in Patients with Rheumatoid Arthritis. Mod Rheumatol. 2022;Mar 26;roac029. doi: 10.1093/mr/roac029.Rákóczi É, Perge B, Végh E, et al. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept.Joint Bone Spine. 2016. 83(6):675–679.Rákóczi É, Perge B, Végh E, et al. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine. 2016;Dec;83(6):675–679. doi: 10.1016/j.jbspin.2015.10.017.Caporuscio S, Ieraci R, Valesini G, et al. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. Clin Immunol. 2018. 195:18–27.Caporuscio S, Ieraci R, Valesini G, et al. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. Clin Immunol. 2018;Oct;195:18–27. doi: 10.1016/j.clim.2018.07.010.Aalst MV, Langedijk AC, Spijker R, et al. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine. 2018.36(39):5832–45.Aalst MV, Langedijk AC, Spijker R, et al. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine. 2018;36(39):5832–45. doi: 10.1016/j.vaccine.2018.07.039.Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012. 130(3 Suppl):S1–24.Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;Sep;130(3 Suppl):S1–24. doi: 10.1016/j.jaci.2012.07.002.Daly TM, Harry R, Hill HR. Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function. Clin Vaccine Immunol. 2015. 22(2):148–52.Daly TM, Harry R, Hill HR. Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function. Clin Vaccine Immunol. 2015; Feb;22(2):148–52. doi: 10.1128/CVI.00735-14.Park MA, Jenkins SM, Smith CY, et al. Pneumococcal serotype-specific cut-offs based on antibody responses to pneumococcal polysaccharide vaccination in healthy adults. Vaccine. 2021. 39:2850–2856.Park MA, Jenkins SM, Smith CY, et al. Pneumococcal serotype-specific cut-offs based on antibody responses to pneumococcal polysaccharide vaccination in healthy adults. Vaccine. 2021. 39:2850–2856.Beck SC. Making sense of serotype-specific pneumococcal antibody measurements. Ann Clin Biochem. 2013. 50(Pt 6):517–9.Beck SC. Making sense of serotype-specific pneumococcal antibody measurements. Ann Clin Biochem. 2013; Nov;50(Pt 6):517–9. doi: 10.1177/0004563213500241.LaFon DC, Nahm MH. Measuring immune responses to pneumococcal vaccines. J Immunol Methods. 2018. 461:37–43.LaFon DC, Nahm MH. Measuring immune responses to pneumococcal vaccines. J Immunol Methods. 2018; Oct;461:37–43. doi: 10.1016/j.jim.2018.08.002.Burton RL, Antonello J, Cooper D, et al. Assignment of opsonic values to pneumococcal reference serum 007sp for use in opsonophagocytic assays for 13 serotypes. Clin Vaccine Immunol. 2017. 6;24(2):e00457–16.40.Burton RL, Antonello J, Cooper D, et al. Assignment of opsonic values to pneumococcal reference serum 007sp for use in opsonophagocytic assays for 13 serotypes. Clin Vaccine Immunol. 2017; Feb 6;24(2):e00457–16. doi: 10.1128/CVI.00457-16.Rose CE, Romero-Steiner S, Burton RL, et al. Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol. 2011. 18(1):135–42.Rose CE, Romero-Steiner S, Burton RL, et al. Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol. 2011;Jan;18(1):135–42. doi: 10.1128/CVI.00370-10.Furer V, Rondaan C, Heijstek MW, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019. 19;5(2):e001041.Furer V, Rondaan C, Heijstek MW, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; Sep 19;5(2):e001041. doi: 10.1136/rmdopen-2019-001041Белов Б. С., Тарасова Г. М., Муравьева Н. В. Вакцинация в ревматологии - 2019 (по материалам рекомендаций EULAR). Научно-практическая ревматология. 2019.57(6):618–625.Belov BS, Tarasova GM, Muravyevа NV. Vaccination in rheumatology (the 2019 update of EULAR recommendations). Rheumatology Science and Practice. 2019;57(6):618–625 (In Russ.). doi: 10.14412/1995-4484-2019-618-625.Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2023 Jan 4Bass AR, Chakravarty E, Akl EA et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken) . 2023 Jan 4. doi: 10.1002/acr.25045. Online ahead of print.Клинические рекомендации «Ревматоидный артрит» (утв. Министерством здравоохранения РФ (18.10.2021).Clinical recommendations «Rheumatoid arthritis» (approved by the Ministry of Health of the Russian Federation (18.10.2021). ID: KP250. (In Russ.).

The authors declare that there are no conflicts of interest present.